Literature DB >> 34984913

Attitudes toward pharmacogenetics in patients undergoing CYP2C19 testing following percutaneous coronary intervention.

Grace Lee1, Lisa A Varughese2, Laura Conway1,2, Carol Stojinski3, Sandhya Ashokkumar3, Karen Monono2, William Matthai4, Daniel M Kolansky4, Jay Giri4,5, Sony Tuteja2.   

Abstract

Aim: Patient knowledge and attitudes toward pharmacogenetic (PGx) testing may impact adoption of clinical testing.
Methods: Questionnaires regarding knowledge, attitudes and ethics of PGx testing were distributed to 504 patients enrolled in the ADAPT study conducted at two urban hospitals in Philadelphia, Pennsylvania, USA. Responses were assessed using multivariable logistic regression.
Results: 311 completed the survey (62% response rate). 74% were unaware of PGx testing, but 79% indicated using PGx results to predict medication efficacy was important. In a multivariable model, higher education level (p = 0.031) and greater genetics knowledge (p < 0.001) were associated with more positive attitudes toward PGx testing.
Conclusion: Greater patient knowledge of genetics was associated with a more positive attitude toward PGx testing, indicating that educational strategies aimed at increasing genetics knowledge may enhance adoption of PGx testing in the clinic.

Entities:  

Keywords:  clopidogrel; cytochrome P450 CYP2C19; patient acceptance of healthcare; patient attitudes; pharmacogenetic testing; pharmacogenetics; precision medicine; survey

Mesh:

Substances:

Year:  2022        PMID: 34984913      PMCID: PMC8885847          DOI: 10.2217/pme-2021-0064

Source DB:  PubMed          Journal:  Per Med        ISSN: 1741-0541            Impact factor:   2.512


  29 in total

1.  Perspectives on Precision Health Among Racial/Ethnic Minority Communities and the Physicians That Serve Them.

Authors:  Lisa G Rosas; Catherine Nasrallah; Van Ta Park; Jan J Vasquez; Ysabel Duron; Owen Garrick; Riccesha Hattin; Mildred Cho; Sean P David; Jill Evans; Rhonda McClinton-Brown; Christopher Martin
Journal:  Ethn Dis       Date:  2020-04-02       Impact factor: 1.847

2.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Authors:  Jean-Sébastien Hulot; Alessandra Bura; Eric Villard; Michel Azizi; Véronique Remones; Catherine Goyenvalle; Martine Aiach; Philippe Lechat; Pascale Gaussem
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

3.  Public perspectives about pharmacogenetic testing and managing ancillary findings.

Authors:  Susanne B Haga; Genevieve Tindall; Julianne M O'Daniel
Journal:  Genet Test Mol Biomarkers       Date:  2011-11-02

4.  Patients' and physicians' perspectives on pharmacogenetic testing.

Authors:  Anja Rogausch; Daniela Prause; Anne Schallenberg; Jürgen Brockmöller; Wolfgang Himmel
Journal:  Pharmacogenomics       Date:  2006-01       Impact factor: 2.533

5.  Public perceptions of pharmacogenetics.

Authors:  Steven C Zhang; Carleton Bruce; Michael Hayden; Michael J Rieder
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

6.  Views on personalized medicine: do the attitudes of African American and white prescription drug consumers differ?

Authors:  M De Marco; S Cykert; N Coad; K Doost; J Schaal; B White; D Young; M R Isler; G Corbie-Smith
Journal:  Public Health Genomics       Date:  2009-09-23       Impact factor: 2.000

7.  Public knowledge of and attitudes toward genetics and genetic testing.

Authors:  Susanne B Haga; William T Barry; Rachel Mills; Geoffrey S Ginsburg; Laura Svetkey; Jennifer Sullivan; Huntington F Willard
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-13

Review 8.  Collaborative Counseling Considerations for Pharmacogenomic Tests.

Authors:  Heather A Zierhut; Colleen A Campbell; Allison G Mitchell; Amy A Lemke; Rachel Mills; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2017-08-07       Impact factor: 4.705

9.  Development and Initial Assessment of a Patient Education Video about Pharmacogenetics.

Authors:  Rachel Mills; Megan Ensinger; Nancy Callanan; Susanne B Haga
Journal:  J Pers Med       Date:  2017-05-25

Review 10.  Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review.

Authors:  Katie E J Hann; Madeleine Freeman; Lindsay Fraser; Jo Waller; Saskia C Sanderson; Belinda Rahman; Lucy Side; Sue Gessler; Anne Lanceley
Journal:  BMC Public Health       Date:  2017-05-25       Impact factor: 3.295

View more
  1 in total

1.  Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy.

Authors:  Ramzi G Salloum; Jeffrey R Bishop; Amanda L Elchynski; D Max Smith; Elizabeth Rowe; Kathryn V Blake; Nita A Limdi; Christina L Aquilante; Jill Bates; Amber L Beitelshees; Amber Cipriani; Benjamin Q Duong; Philip E Empey; Christine M Formea; J Kevin Hicks; Pawel Mroz; David Oslin; Amy L Pasternak; Natasha Petry; Laura B Ramsey; Allyson Schlichte; Sandra M Swain; Kristen M Ward; Kristin Wiisanen; Todd C Skaar; Sara L Van Driest; Larisa H Cavallari; Sony Tuteja
Journal:  Implement Sci Commun       Date:  2022-05-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.